Craig Collard compensation by year
Heron Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $492,986 | $669,500 | $689,431 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $547,273 | $461,368 | $946,254 |
| Option awards | $9,257,049 | $1,687,180 | $1,352,917 |
| Non-equity incentive | $326,957 | $577,444 | $517,189 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $151,553 | $0 | $10,500 |
| Total | $10,775,818 | $3,395,492 | $3,516,291 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Heron Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-196306, and prior-year filings.
How this page was built: the Heron Therapeutics, Inc. filed document, accession 0001193125-26-196306. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 1,887,642 | $2,453,934 | — |
| RSU | 452,254 | $587,930 | — |
| RSU | 125,000 | $162,500 | — |
| RSU | 124,172 | $161,424 | — |
| RSU | 11,837 | $15,388 | — |
| Option | 2,000,000 | — | $1.78 |
| Option | 112,358 | — | $1.78 |
| Option | 689,845 | — | $2.09 |
| Option | 858,122 | — | $1.70 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Heron Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
19 Form 4 lines since the FY2025 proxy (filed April 30, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-31 | Exercise or conversion derivative | — | 34,788 | $0.00 | 313,098 |
| 2026-10-31 | Tax withholding | — | 8,471 | $0.28 | 931,086 |
| 2026-10-31 | Exercise or conversion | — | 34,788 | — | 939,557 |
| 2026-10-30 | Tax withholding | — | 12,181 | $0.28 | 904,769 |
| 2026-10-30 | Exercise or conversion | — | 50,021 | — | 916,950 |
| 2026-10-30 | Exercise or conversion derivative | — | 50,021 | $0.00 | 650,274 |
| 2026-10-19 | Exercise or conversion | — | 13,797 | — | 870,289 |
| 2026-10-19 | Tax withholding | — | 3,360 | $0.36 | 866,929 |
The 8 most recent of 19 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Heron Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $689,585 | $4,727,242 | $47,078 | $5,981,094 |
| Involuntary termination without cause | $689,585 | $346,207 | $47,078 | $1,600,059 |
Per the Potential Payments Upon Termination or Change in Control table in Heron Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Heron Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mark Hensley | EVP, Chief Operating Officer | $4,307,500 |
| Craig Collard · this page | Chief Executive Officer | $3,516,291 |
| William Forbes | EVP, Chief Development Officer | $1,687,765 |
| Ira Duarte | EVP, Chief Financial Officer | $1,630,678 |
Board service
Heron Therapeutics board · FY2024–FY2025How this board is paid
Company policy: Heron Therapeutics pays directors a $50,000 cash retainer. As stated in Heron Therapeutics's FY2025 proxy.
The full Heron Therapeutics compensation record
free company briefThis page is one person within Heron Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Heron Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Heron Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Heron Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.